3-Deazaneplanocin A - CAS 102052-95-9
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
3-Deazaneplanocin A
Catalog Number:
B0084-462897
CAS Number:
102052-95-9
Description:
3-Deazaneplanocin A (DZNep), an inhibitor of S-adenosylmethionine-dependent methyltransferase that targets the degradation of EZH2.
Molecular Weight:
262.26
Molecular Formula:
C12H14N4O3
COA:
Inquire
MSDS:
Inquire
Targets:
EZH2
Catalog Number Size Price Stock Quantity
B0084-462897 10 mg $1998 In stock
Bulk Inquiry
Chemical Structure
CAS 102052-95-9 3-Deazaneplanocin A

Related EZH2 Products


EPZ011989
(CAS: 1598383-40-4)

EPZ011989 is a potent, orally-available EZH2 inhibitor with robust in vivo activity. EPZ011989 demonstrates significant tumor growth inhibition in a mouse xenog...

CAS 1431612-23-5 UNC-1999

UNC-1999
(CAS: 1431612-23-5)

UNC1999, the first orally bioavailable inhibitor that has high in vitro potency for wildtype and mutant EZH2 as well as EZH1. UNC1999 was highly selective for E...

CPI-360
(CAS: 1802175-06-9)

CPI-360 is a potent, selective,and SAM-competitive EZH1 inhibitor with IC50 of 102.3 nM, >100-fold selectivity over other methyltransferases.

CAS 120964-45-6 3-deazaneplanocin A (DZNeP) HCl

3-deazaneplanocin A (DZNeP) HCl
(CAS: 120964-45-6)

3-deazaneplanocin A (DZNeP)HCl, an analog of adenosine, is a competitive inhibitor of S-adenosylhomocysteine hydrolase with Ki of 50 pM.

CAS 1346704-33-3 GSK343

GSK343
(CAS: 1346704-33-3)

GSK343 is a potent, selective inhibitor of EZH2 with cellular activity. GSK343 inhibits EZH2 with an IC50 of 4nM and is over 1000-fold selective for other HMTs...

CAS 102052-95-9 3-Deazaneplanocin A

3-Deazaneplanocin A
(CAS: 102052-95-9)

3-Deazaneplanocin A (DZNep), an inhibitor of S-adenosylmethionine-dependent methyltransferase that targets the degradation of EZH2.

CAS 1403254-99-8 EPZ-6438

EPZ-6438
(CAS: 1403254-99-8)

EPZ-6438 is a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity. EPZ-6438 induces apoptosis and differentiation ...

ZLD1039
(CAS: 1826865-46-6)

ZLD1039 potent, highly selective, and orally bioavailable small molecule inhibitor of EZH2, which inhibited the methyltransferase activity of EZH2 with high se...

CAS 1346574-57-9 GSK126

GSK126
(CAS: 1346574-57-9)

GSK126 is a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity. GSK126 decreases global H3...

GSK-503
(CAS: 1346572-63-1)

GSK-503 is a potent EZH2 inhibitor with potential anticancer activity. Increased activity of the epigenetic modifier EZH2 has been associated with different can...

CAS 1418308-27-6 EI1

EI1
(CAS: 1418308-27-6)

EI1 inhibits cellular H3K27 methylation and activates Ezh2 target gene p16 expression.

CAS 1450655-76-1 CPI-169

CPI-169
(CAS: 1450655-76-1)

CPI-169 is a novel and potent EZH2 inhibitor, it decreases cellular levels of H3K27me3 and triggers cell cycle arrest and apoptosis in a variety of cell lines.

EPZ011989 trifluoroacetate
(CAS: 1598383-41-5)

EPZ011989 trifluoroacetate is the trifluoroacetate salt form of EPZ011989. EPZ011989 is a potent and orally bioavailable inhibitor that specifically targets the...

CAS 1396772-26-1 EPZ005687

EPZ005687
(CAS: 1396772-26-1)

EPZ005687 is a selective EZH2 enzyme inhibitor with Ki of 24 nM. It is 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyl...

Reference Reading


1.3-Deazaneplanocin A suppresses aggressive phenotype-related gene expression in an oral squamous cell carcinoma cell line.
Hatta M1, Naganuma K2, Kato K3, Yamazaki J3. Biochem Biophys Res Commun. 2015 Dec 4-11;468(1-2):269-73. doi: 10.1016/j.bbrc.2015.10.115. Epub 2015 Oct 23.
In tumor tissues, alterations of gene expression caused by aberrant epigenetic modifications confer phenotypic diversity on malignant cells. Although 3-deazaneplanocin A (DZNep) has been shown to reactivate tumor suppressor genes in several cancer cells, it remains unclear whether DZNep attenuates the malignant phenotypes of oral squamous cell carcinoma (OSCC) cells. In this study, we investigated the effect of DZNep on the expression of genes related to aggressive phenotypes, such as epithelial-mesenchymal transition, in OSCC cells. We found that DZNep reduced the cellular levels of polycomb group proteins (EZH2, SUZ12, BMI1, and RING1A) and the associated trimethylation of Lys27 on histone H3 and monoubiquitination of Lys119 on histone H2A in the poorly differentiated OSCC cell line SAS. Immunocytochemical staining demonstrated that DZNep induced the reorganization of filamentous actin and the membrane localization of E-cadherin associated with cell-cell adhesions.
2.Growth Inhibition Accompanied by MOB1 Upregulation in Human Acute Lymphoid Leukemia Cells by 3-Deazaneplanocin A.
Shen J1, Su J, Wu D, Zhang F, Fu H, Zhou H, Xu M. Biochem Genet. 2015 Oct;53(9-10):268-79. doi: 10.1007/s10528-015-9688-7. Epub 2015 Aug 23.
Our purpose was to investigate the effect of 3-deazaneplanocin A (DZNep) on human T-cell acute lymphoid leukemia (T-ALL) cells, and to explore the underlying molecular mechanisms. The human T-ALL cell line Molt4 was treated with DZNep, and cell proliferation was examined. The expression of Mps one binder kinase activator 1 gene (MOB1) mRNA and protein was determined by RT-PCR and Western blotting, respectively. The histone modification effect of DZNep on the lysine 9 of histone 3 associated with MOB1 promoters was examined with chromatin immunoprecipitation and quantitative PCR, and CpG methylation in MOB1 promoters was detected by bisulfite sequencing PCR. DZNep treatment inhibited the growth of Molt4 cells. The expressions of MOB1 genes were upregulated by DZNep treatment, and histone methylations in their promoters were significantly reduced. The results indicate that DZNep is a promising therapeutic compound for the treatment of human T-ALL.